Phase 3 post-hoc analysis indicates less fentanyl and overall illicit opioid use for weekly/monthly buprenorphine depots versus daily standard treatment in a difficult to treat patient population LUND ...

- Individualized treatment of opioid dependence with weekly and monthly Buvidal ® was well-tolerated and effective, with a high (73.6%) patient retention across the 48-week study - 83.4% of ...

Camurus, a Swedish research-based pharmaceutical company, announced that the European Commission (EC) has approved weekly and monthly Buvidal (prolonged release buprenorphine) for the treatment of ...

LUND, Sweden, Nov. 26, 2019 /PRNewswire/ -- Camurus announced today topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal® (prolonged-release ...

Camurus, a Swedish, science-led biopharmaceutical company, announced topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal (prolonged-release ...

The EU’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a new dose of Camurus’ prolonged-release injection opioid dependence treatment. Buvidal, which contains ...

LUND, Sweden, Nov. 22, 2018 /PRNewswire/ -- Camurus announced today that the European Commission (EC) has approved weekly and monthly Buvidal® (prolonged release buprenorphine) for the treatment of ...

To overcome problematic opioid use, traditional forms of opioid substitution therapy, such as methadone and oral buprenorphine, have become valuable tools. Research shows that patients receiving ...

The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor, nurse practitioner or pharmacist. Buvidal contains the active ingredient ...

Scott Hallion says he was a “full-blown cocaine addict” by the time he was 14. Five years later, he was in prison and heroin entered his life for the first time. From Rathmines in Dublin, Hallion says ...